TLR7 Agonist Imiquimod Improves the Therapeutic Antitumor Effect of High–Dose–Rate Brachytherapy
Authors:
- Magdalena Jarosz-BiejMJMagdalena Jarosz-Biej
- Ryszard SmolarczykRSRyszard Smolarczyk
- Dorota Sprus-LipkaDSDorota Sprus-Lipka
- Marta SzlagMSMarta Szlag
- Zbigniew UrbaśZUZbigniew Urbaś
- Justyna CzaplaJCJustyna Czapla
- Joanna CiepłaJCJoanna Ciepła
- Karolina SinekKSKarolina Sinek
- Alina DrzyzgaADAlina Drzyzga
- Ewelina PilnyEPEwelina Pilny
- Piotr WojcieszekPWPiotr Wojcieszek
- Tomasz CichońTCTomasz Cichoń
Open Access
Abstract
Background/Objectives: Brachytherapy (BT) is a local radiation treatment method for solid tumors. A single 10 Gy high–dose–rate (HDR) BT acts as an “in situ” vaccination. Tumor microenvironment (TME)–dependent radio–resistance mechanisms, such as increasing immunosuppression and hypoxia, lead to tumor recurrence after radiotherapy. Our study aimed to determine whether adding imiquimod (IMQ) to anticancer therapy would overcome TME–mediated mechanisms of radiotherapy resistance. IMQ, a toll–like receptor 7 (TLR7) agonist, acts as an immunostimulant and a vascular normalizing agent. Methods: Mice with well–developed tumors were treated with IMQ at a vascular–normalized dose of 50 μg, followed 5 days later by a single 10 Gy HDR BT. The dose coverage was planned using Discovery RT computed tomography CT scans. Irradiation was performed with a high–dose–rate afterloader equipped with an iridium–192 radioactive source. Results: In mice treated with a combination of IMQ and BT, we observed significant inhibition of melanoma tumor growth. We also noticed an effective therapeutic effect in mice with breast cancer, resulting in significantly prolonged survival and complete tumor regression in 20% of treated mice. In the blood of treated mice, we observed leukopenia with eosinophilia. In tumors, there was enhanced infiltration by cytotoxic CD8+ T lymphocytes. The depletion of CD8+ T cells completely abolished the effect of the combined therapy. Conclusions: The combination of IMQ with HDR brachytherapy induces a synergistic effect, improving the therapeutic antitumor effect of brachytherapy. Our data indicate that it is reasonable to use drugs that prevent changes in the TME in combination with radiotherapy.Keywords
Funding Information
- Narodowe Centrum Nauki (2018/31/D/NZ5/01754)
This publication has 29 references indexed in Scilit:
- Enhancing antitumor immunity through the combination of cholesterolized TLR7 agonist liposomes and radiotherapy: a role for IL‐1β and the inflammasome pathwayCancer Communications, 2025
- Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonistCancer Immunology, Immunotherapy, 2025
- Brachytherapy: Perspectives for combined treatments with immunotherapyClinical and Translational Radiation Oncology, 2025
- Radiobiology and modelling in Brachytherapy: A review inspired by the ESTRO Brachytherapy pre-meeting courseClinical and Translational Radiation Oncology, 2024
- Combination of radiotherapy and immunotherapy in duality with the protumoral action of radiationCancer/Radiothérapie, 2024
- Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeationDrug Delivery and Translational Research, 2024
- “Reinforcement” by Tumor Microenvironment: The Seventh “R” of RadiobiologyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Clinical Radiobiology for Radiation Oncology2023
- The American Brachytherapy society consensus statement for skin brachytherapyBrachytherapy, 2020
- Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunitiesBrachytherapy, 2019